Latest news and press releases about aTyr Pharma, Inc. (ATYR): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
aTyr Pharma, Inc., a biopharmaceutical firm established in San Diego, California, in 2005, is dedicated to the discovery and advancement of therapeutic solutions. Operating within the United States, the company's research focuses on pioneering novel immunological pathways to address various medical conditions. Its primary investigational drug, efzofitimod, functions as a selective modulator of NRP2.
Price
| Price | $0.38 |
| Market Cap | $38M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 0.72 |
| EV / EBITDA | -1.02 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -109.84% |
| Return on Invested Capital | -96.45% |
| Return on Assets | -78.71% |
| Gross Margin | -11754.74% |
| Operating Margin | -33609.47% |
| Net Margin | -32003.68% |
Related companies: ACRV · ALXO · CAMP · DTIL · HYFT · MGX · QNCX
Explore sector: Healthcare · Biotechnology
More sections of ATYR: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks